Psoriasis biologics: a new era of choice
- PMID: 31402113
- DOI: 10.1016/S0140-6736(19)31772-6
Psoriasis biologics: a new era of choice
Comment on
-
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8. Lancet. 2019. PMID: 31402114 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
